Clinical trial
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced…
NCT00083213 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00083213 |
|---|---|
| Title | Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
| Official title | An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Biological |
| Interventions | ziv-aflibercept |
| Enrollment | 25 |
| Start date | Jan 1, 2004 |
| Primary completion | May 1, 2008 |
| First posted | May 19, 2004 |
| Last update posted | Jun 3, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: